Used in research and development of immunotherapies targeting melanoma and other GD3-expressing tumors. Binds specifically to the GD3 ganglioside antigen found on the surface of certain cancer cells, enabling targeted delivery of therapeutic agents or facilitating immune-mediated cell destruction. Investigated for use in monoclonal antibody therapy, antibody-drug conjugates (ADCs), and diagnostic imaging. Also serves as a reference standard in preclinical studies to evaluate binding affinity, specificity, and functional activity of anti-GD3 antibodies.